Cybin Rallies After Steve Cohen’s Point 72 Disclosed 8.1% Equity Purchase
Renowned hedge fund manager and Wall Street mogul Steve Cohen is showing his confidence in the psychedelic sector. Cohen’s hedge
Read moreRenowned hedge fund manager and Wall Street mogul Steve Cohen is showing his confidence in the psychedelic sector. Cohen’s hedge
Read moreFilament Health (NEO: FH) is claiming that shareholders are about to receive US$0.85 per share in value following an agreement
Read moreThe White House and its surroundings were temporarily evacuated on Sunday following the discovery of an unknown substance on the
Read moreThe U.S. Food and Drug Administration (FDA) has released a groundbreaking draft guidance to provide crucial insights for researchers exploring
Read moreJeffrey Stevens, CEO & Director of Psyched Wellness (CSE: PSYC) joins us in today’s episode of the Daily Dive. Jeff
Read moreLast week, Quebec became the first governing medical body in Canada to publicly fund medical psilocybin-assisted psychotherapy, with advocates hoping
Read moreMind Medicine (NEO: MMED) has elected to destroy shareholder value in a major way this morning, pricing yet another financing
Read morePhase 1 trials are officially underway for Bright Minds Biosciences (CSE: DRUG) and their lead product, referred to as BMB-101.
Read moreMind Medicine (NEO: MMED) might be slightly more volatile over the next few sessions. The psychedelic firm late on Friday
Read moreMind Medicine (NEO: MMED) has officially seen patient trials under a Phase 2b study get underway as it looks to
Read more